Janus Henderson Group
EIGR

Janus Henderson Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Janus Henderson Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,706
Closed -$3.09M – 2531
2022
Q3 		$3.09M Buy
+13,706
New +$3.37M ﹤0.01% 1137

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Janus Henderson Group's EIGR Position: Q4 2022 in Review

Janus Henderson Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 13,706 shares — an estimated $3.09M sold.

Janus Henderson Group first reported a position in EIGR in Q3 2022 and held it in 1 quarter. The position peaked at $3.09M in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Janus Henderson Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Janus Henderson Group sold 13,706 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $3.09M.
  • Janus Henderson Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Janus Henderson Group's Eiger BioPharmaceuticals, Inc. position peaked at $3.09M in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.